A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
In a phase 2 trial, inhaled nitrous oxide at 25% concentration improved symptoms of treatment‑resistant major depression and produced fewer adverse effects than the 50% concentration.
Authors
- Nagele, P.
- Palanca, B. J.
- Gott, B.
Published
Abstract
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration.
Research Summary of 'A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression'
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- APA Citation
Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., Jain, N., Cheng, W. W. L., Komen, H., Yee, B., Bolzenius, J. D., Janski, A., Gibbons, R., Zorumski, C. F., & Conway, C. R. (2021). A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Science Translational Medicine, 13(597). https://doi.org/10.1126/scitranslmed.abe1376
References (2)
Papers cited by this study that are also in Blossom
Nagele, P., Duma, A., Kopec, M. et al. · Biological Psychiatry (2015)
Ari, A., Abdallah, C. G., Sanacora, G. et al. · Annual Review of Medicine (2014)
Cited By (3)
Papers in Blossom that reference this study
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Lii, T. R., Smith, A. E., Flohr, J. R. et al. · Nature Mental Health (2023)
Dai, R., Larkin, T. E., Huang, Z. et al. · NeuroImage (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.